Phase I trials for an Eppstein Barr vaccine are being initiated

[Rufous McKinney]

Below are the Phase I protocols for a study of a potential Eppstein Barr vaccine....

https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=21-I-0005&&query=epstein-barr

 

[lenora]

Hello @Rufous McKinney.....Interesting and I'll pass this info along to my daughters as two of my grandchildren are at this particular age. Thinking about it, neither of my two (ages 50 & 47) never had EBV, which I consider to be a minor miracle, especially in the college years.

So many choices to make....Yours (& thanks)....Lenora.

 

[SnappingTurtle]

This is good to hear. As my ME was triggered by EBV which was bad enough by itself, I would like to save others the suffering.

 

[Breagjam]

This is excellent news. This vaccine would be long overdue.

 

[Rufous McKinney]

Thinking about it, neither of my two (ages 50 & 47) never had EBV, which I consider to be a minor miracle, especially in the college years.

well we shall see- we are told everybody just about ends up exposed, and I can confirm kissing isn't involved.

So it might be something you'd need to get really young, not wait til college.

My older brother claims he never had mono. I'm not sure he really even would remember.

 

[Lieselotte]

I never remember having mono. Then later, when I got CFS and was tested for viruses, it showed a probable reactivation of EBV. What, I thought! I had figured I got away with never having it!

So everyone who claims they've never had it...well, that may not necessarily be true...

 

[Rufous McKinney]

This paper discusses the theories behind this type of vaccine for Eppstein Barr- 2015

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757492/

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Masaru Kanekiyo, Wei Bu, [...], and Gary J. Nabel

from the abstract-

...
By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine increased neutralization 10- to 100-fold compared to soluble gp350 by targeting a functionally conserved site of vulnerability, improving vaccine-induced protection in a mouse model. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by arrayed presentation of a conserved viral entry domain, a strategy that can be applied to other viruses.

 

[junkcrap50]

Wonder if it would do anything/help CFS or EBV reactivation if taken after getting EBV.

 

[Rufous McKinney]

EBV reactivation if taken after getting EBV.

My immediate thought was this will never help me, but maybe it can help many others in the future.

But if it would go after reactivitations? Which we may experience?

Maybe we could suggest they include a large COHORT of existing victims, and gather data on us concurrently in Phase II and III. THey have lots of clients.

(Oh, wonder what it will cost).